Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06300593
Other study ID # 1072.6120.292.2022-1
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 15, 2024
Est. completion date June 30, 2024

Study information

Verified date March 2024
Source Jagiellonian University
Contact Iwona Gawron, PhD, MD
Phone +48 124248570
Email iwona.gawron@uj.edu.pl
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Chronic inflammation in polycystic ovary syndrome (PCOS) may be the result of dysregulation of cytokine production (due to insulin resistance, excess visceral fat and hyperandrogenemia), i.e., overproduction of pro-inflammatory factors (e.g. TNF, IL-1, IL-6) in relation to anti-inflammatory ones (IL-10). This condition may be an important link between obesity and insulin resistance, which is crucial in the etiopathogenesis of the syndrome. However, it is not known whether it results from the tendency to accumulate adipose tissue or is a feature of the syndrome itself. There is no data indicating the relationship between chronic inflammation and the severity of metabolic disorders and the value of ovarian reserve in women with various PCOS phenotypes.


Description:

The study population will be characterized in terms of demographic (age, BMI), gynaecological (cycle length, menstrual pain, abnormal uterine bleeding) and obstetrics (pregnancies, childbirth, miscarriages) data. PCOS syndrome (and its phenotypes: A, B, C, D) will be recognized by the Rotterdam criteria. During hospitalization, blood samples will be collected for scheduled analyses (20 ml of blood in total).


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date June 30, 2024
Est. primary completion date June 1, 2024
Accepts healthy volunteers
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - age 18-45 years - PCOS syndrome confirmed by the Rotterdam criteria Exclusion Criteria: - absence of at least one ovary - diagnosed and/or treated other metabolic disease - diagnosed and/or treated other endocrine disease

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Measurement and comparison of leucocytosis and concentrations of C-reactive protein (CRP), interleukin-1 (IL-1), IL-6, IL-10, Tumor Necrosis Factor (TNF-alpha) in PCOS phenotypes A, B, C and D
A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to determine and compare the above parameters of peripheral blood in the four study arms
Evaluation of the correlation of serum concentrations of selected inflammatory markers (leucocytosis, CRP, IL-1, IL-6, IL-10, TNF-alpha) with metabolic and hormonal parameters
A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to test the above correlations in the four study arms

Locations

Country Name City State
Poland Jagiellonian University Medical College Krakow

Sponsors (1)

Lead Sponsor Collaborator
Jagiellonian University

Country where clinical trial is conducted

Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Values of inflammation parameters - leukocytosis in peripheral blood in the four PCOS phenotypes Measurement and comparison of leukocyte count (n/µL) in peripheral blood in the four PCOS phenotypes up to 3 months
Primary Values of inflammation parameters - C-reactive protein (CRP) in peripheral blood in the four PCOS phenotypes Measurement and comparison of concentrations of CRP (mg/l) in peripheral blood in the four PCOS phenotypes up to 3 months
Primary Values of inflammation parameters - IL-1 in peripheral blood in the four PCOS phenotypes Measurement and comparison of concentrations of IL-1 (pg/ml) in peripheral blood in the four PCOS phenotypes up to 3 months
Primary Values of inflammation parameters - IL-6 in peripheral blood in the four PCOS phenotypes Measurement and comparison of concentrations of IL-6 (pg/ml) in peripheral blood in the four PCOS phenotypes up to 3 months
Primary Values of inflammation parameters - IL-10 in peripheral blood in the four PCOS phenotypes Measurement and comparison of concentrations of IL-10 (pg/ml) in peripheral blood in the four PCOS phenotypes up to 3 months
Primary Values of inflammation parameters - TNF-alpha in peripheral blood in the four PCOS phenotypes Measurement and comparison of concentrations of TNF-alpha (pg/ml) in peripheral blood in the four PCOS phenotypes up to 3 months
Secondary Correlation between the HOMA-IR value and the parameters of inflammation - leukocytosis in the four PCOS phenotypes Evaluation of the correlation between the HOMA-IR value and inflammatory parameters: leukocyte count (n/µL) up to 3 months
Secondary Correlation between the homeostatic model assessment for insulin resistance (HOMA-IR) value and the parameters of inflammation - CRP in the four PCOS phenotypes Evaluation of the correlation between the HOMA-IR value and inflammatory parameters: CRP (mg/l) up to 3 months
Secondary Correlation between the HOMA-IR value and the parameters of inflammation - il-1 in the four PCOS phenotypes Evaluation of the correlation between the HOMA-IR and inflammatory parameters: il-1 (pg/ml) up to 3 months
Secondary Correlation between the HOMA-IR value and the parameters of inflammation - il-6 in the four PCOS phenotypes Evaluation of the correlation between HOMA-IR value and inflammatory parameters: il-6 (pg/ml) up to 3 months
Secondary Correlation between the concentration of HOMA-IR and the parameters of inflammation - il-10 in in the four PCOS phenotypes Evaluation of the correlation between the concentration of HOMA-IR and inflammatory parameters: il-10 (pg/ml) up to 3 months
Secondary Correlation between the HOMA-IR value and the parameters of inflammation - TNF-alpha in the four PCOS phenotypes Evaluation of the correlation between the HOMA-IR value and inflammatory parameters: TNF-alpha (pg/ml) up to 3 months
Secondary Correlation between the body mass index (BMI) value and the parameters of inflammation - leukocytosis in the four PCOS phenotypes Evaluation of the correlation between the BMI value and inflammatory parameters: leukocyte count (n/µL) up to 3 months
Secondary Correlation between the BMI value and the parameters of inflammation - CRP in the four PCOS phenotypes Evaluation of the correlation between the BMI value and inflammatory parameters: CRP (mg/l) up to 3 months
Secondary Correlation between the BMI value and the parameters of inflammation - il-1 in the four PCOS phenotypes Evaluation of the correlation between the BMI and inflammatory parameters: il-1 (pg/ml) up to 3 months
Secondary Correlation between the BMI value and the parameters of inflammation - il-6 in the four PCOS phenotypes Evaluation of the correlation between BMI value and inflammatory parameters: il-6 (pg/ml) up to 3 months
Secondary Correlation between the concentration of BMI and the parameters of inflammation - il-10 in in the four PCOS phenotypes Evaluation of the correlation between BMI value and inflammatory parameters: il-10 (pg/ml) up to 3 months
Secondary Correlation between the BMI value and the parameters of inflammation - TNF-alpha in the four PCOS phenotypes Evaluation of the correlation between the BMI value and inflammatory parameters: TNF-alpha (pg/ml) up to 3 months
Secondary Correlation between the value of aspartate aminotransferase (AST) concentration and the parameters of inflammation - leukocytosis in the four PCOS phenotypes Evaluation of the correlation between AST concentration (U/l) and inflammatory parameters: leukocyte count (n/µL) up to 3 months
Secondary Correlation between the value of AST concentration and the parameters of inflammation - CRP in the four PCOS phenotypes Evaluation of the correlation between AST concentration (U/l) and inflammatory parameters: CRP (mg/l) up to 3 months
Secondary Correlation between the value of AST concentration and the parameters of inflammation - il-1 in the four PCOS phenotypes Evaluation of the correlation between AST concentration (U/l) and inflammatory parameters: il-1 (pg/ml) up to 3 months
Secondary Correlation between the value of AST concentration and the parameters of inflammation - il-6 in the four PCOS phenotypes Evaluation of the correlation between AST concentration (U/l) and inflammatory parameters: il-6 (pg/ml) up to 3 months
Secondary Correlation between the value of AST concentration and the parameters of inflammation - il-10 in in the four PCOS phenotypes Evaluation of the correlation between AST concentration (U/l) and inflammatory parameters: il-10 (pg/ml) up to 3 months
Secondary Correlation between the value of AST concentration and the parameters of inflammation - TNF-alpha in the four PCOS phenotypes Evaluation of the correlation between AST concentration (U/l) and inflammatory parameters: TNF-alpha (pg/ml) up to 3 months
Secondary Correlation between the value of alanine aminotransferase (ALT) concentration and the parameters of inflammation - leukocytosis in the four PCOS phenotypes Evaluation of the correlation between ALT concentration (U/l) and inflammatory parameters: leukocyte count (n/µL) up to 3 months
Secondary Correlation between the value of ALT concentration and the parameters of inflammation - CRP in the four PCOS phenotypes Evaluation of the correlation between ALT concentration (U/l) and inflammatory parameters: CRP (mg/l) up to 3 months
Secondary Correlation between the value of ALT concentration and the parameters of inflammation - il-1 in the four PCOS phenotypes Evaluation of the correlation between ALT concentration (U/l) and inflammatory parameters: il-1 (pg/ml) up to 3 months
Secondary Correlation between the value of ALT concentration and the parameters of inflammation - il-6 in the four PCOS phenotypes Evaluation of the correlation between ALT concentration (U/l) and inflammatory parameters: il-6 (pg/ml) up to 3 months
Secondary Correlation between the value of ALT concentration and the parameters of inflammation - il-10 in in the four PCOS phenotypes Evaluation of the correlation between ALT concentration (U/l) and inflammatory parameters: il-10 (pg/ml) up to 3 months
Secondary Correlation between the value of ALT concentration and the parameters of inflammation - TNF-alpha in the four PCOS phenotypes Evaluation of the correlation between ALT concentration (U/l) and inflammatory parameters: TNF-alpha (pg/ml) up to 3 months
Secondary Correlation between the value of total bilirubin concentration and the parameters of inflammation - leukocytosis in the four PCOS phenotypes Evaluation of the correlation between total bilirubin concentration (mg/dl) and inflammatory parameters: leukocyte count (n/µL) up to 3 months
Secondary Correlation between the value of total bilirubin concentration and the parameters of inflammation - CRP in the four PCOS phenotypes Evaluation of the correlation between total bilirubin concentration (mg/dl) and inflammatory parameters: CRP (mg/l) up to 3 months
Secondary Correlation between the value of total bilirubin concentration and the parameters of inflammation - il-1 in the four PCOS phenotypes Evaluation of the correlation between total bilirubin concentration (mg/dl) and inflammatory parameters: il-1 (pg/ml) up to 3 months
Secondary Correlation between the value of total bilirubin concentration and the parameters of inflammation - il-6 in the four PCOS phenotypes Evaluation of the correlation between total bilirubin concentration (mg/dl) and inflammatory parameters: il-6 (pg/ml) up to 3 months
Secondary Correlation between the value of total bilirubin concentration and the parameters of inflammation - il-10 in in the four PCOS phenotypes Evaluation of the correlation between total bilirubin concentration (mg/dl) and inflammatory parameters: il-10 (pg/ml) up to 3 months
Secondary Correlation between the value of total bilirubin concentration and the parameters of inflammation - TNF-alpha in the four PCOS phenotypes Evaluation of the correlation between total bilirubin concentration (mg/dl) and inflammatory parameters: TNF-alpha (pg/ml) up to 3 months
Secondary Correlation between the value of total cholesterol concentration and the parameters of inflammation - leukocytosis in the four PCOS phenotypes Evaluation of the correlation between total cholesterol concentration (mg/dl) and inflammatory parameters: leukocyte count (n/µL) up to 3 months
Secondary Correlation between the value of total cholesterol concentration and the parameters of inflammation - CRP in the four PCOS phenotypes Evaluation of the correlation between total cholesterol concentration (mg/dl) and inflammatory parameters: CRP (mg/l) up to 3 months
Secondary Correlation between the value of total cholesterol concentration and the parameters of inflammation - il-1 in the four PCOS phenotypes Evaluation of the correlation between total cholesterol concentration (mg/dl) and inflammatory parameters: il-1 (pg/ml) up to 3 months
Secondary Correlation between the value of total cholesterol concentration and the parameters of inflammation - il-6 in the four PCOS phenotypes Evaluation of the correlation between total cholesterol concentration (mg/dl) and inflammatory parameters: il-6 (pg/ml) up to 3 months
Secondary Correlation between the value of total cholesterol concentration and the parameters of inflammation - il-10 in in the four PCOS phenotypes Evaluation of the correlation between total cholesterol concentration (mg/dl) and inflammatory parameters: il-10 (pg/ml) up to 3 months
Secondary Correlation between the value of total cholesterol concentration and the parameters of inflammation - TNF-alpha in the four PCOS phenotypes Evaluation of the correlation between total cholesterol concentration (mg/dl) and inflammatory parameters: TNF-alpha (pg/ml) up to 3 months
Secondary Correlation between the value of triglycerides concentration and the parameters of inflammation - leukocytosis in the four PCOS phenotypes Evaluation of the correlation between triglycerides concentration (mg/dl) and inflammatory parameters: leukocyte count (n/µL) up to 3 months
Secondary Correlation between the value of triglycerides concentration and the parameters of inflammation - CRP in the four PCOS phenotypes Evaluation of the correlation between triglycerides concentration (mg/dl) and inflammatory parameters: CRP (mg/l) up to 3 months
Secondary Correlation between the value of triglycerides concentration and the parameters of inflammation - il-1 in the four PCOS phenotypes Evaluation of the correlation between triglycerides concentration (mg/dl) and inflammatory parameters: il-1 (pg/ml) up to 3 months
Secondary Correlation between the value of triglycerides concentration and the parameters of inflammation - il-6 in the four PCOS phenotypes Evaluation of the correlation between triglycerides concentration (mg/dl) and inflammatory parameters: il-6 (pg/ml) up to 3 months
Secondary Correlation between the value of triglycerides concentration and the parameters of inflammation - il-10 in in the four PCOS phenotypes Evaluation of the correlation between triglycerides concentration (mg/dl) and inflammatory parameters: il-10 (pg/ml) up to 3 months
Secondary Correlation between the value of triglycerides concentration and the parameters of inflammation - TNF-alpha in the four PCOS phenotypes Evaluation of the correlation between triglycerides concentration (mg/dl) and inflammatory parameters: TNF-alpha (pg/ml) up to 3 months
Secondary Correlation between the value of Anti-Müllerian hormone (AMH) concentration and the parameters of inflammation - leukocytosis in the four PCOS phenotypes Evaluation of the correlation between AMH concentration (pmol/l) and inflammatory parameters: leukocyte count (n/µL) up to 3 months
Secondary Correlation between the value of AMH concentration and the parameters of inflammation - CRP in the four PCOS phenotypes Evaluation of the correlation between AMH concentration (pmol/l) and inflammatory parameters: CRP (mg/l) up to 3 months
Secondary Correlation between the value of AMH concentration and the parameters of inflammation - il-1 in the four PCOS phenotypes Evaluation of the correlation between AMH concentration (pmol/l) and inflammatory parameters: il-1 (pg/ml) up to 3 months
Secondary Correlation between the value of AMH concentration and the parameters of inflammation - il-6 in the four PCOS phenotypes Evaluation of the correlation between AMH concentration (pmol/l) and inflammatory parameters: il-6 (pg/ml) up to 3 months
Secondary Correlation between the value of AMH concentration and the parameters of inflammation - il-10 in in the four PCOS phenotypes Evaluation of the correlation between AMH concentration (pmol/l) and inflammatory parameters: il-10 (pg/ml) up to 3 months
Secondary Correlation between the value of AMH concentration and the parameters of inflammation - TNF-alpha in the four PCOS phenotypes Evaluation of the correlation between AMH concentration (pmol/l) and inflammatory parameters: TNF-alpha (pg/ml) up to 3 months
See also
  Status Clinical Trial Phase
Completed NCT03142633 - MicroRNA as Biomarkers for Development of Metabolic Syndrome in Women With Polycystic Ovary Syndrome
Completed NCT06158932 - A Single Group Study to Evaluate the Effects of a Myo-Inositol and D-Chiro Inositol Supplement on Symptoms Associated With Polycystic Ovary Syndrome and Hormone Imbalance N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Active, not recruiting NCT02500147 - Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS) Phase 4
Completed NCT04932070 - Berberine and Polycystic Ovary Syndrome N/A
Suspended NCT03652987 - Endocrine and Menstrual Disturbances in Women With Polycystic Ovary Syndrome (PCOS)
Completed NCT03480022 - Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS Phase 3
Active, not recruiting NCT03043924 - Functional Study of the Hypothalamus in Magnetic Resonance Imaging (MRI) in Polycystic Ovary Syndrome (PCOS) N/A
Completed NCT05246306 - Aerobic Capacity and Physical Fitness Level of Adolescents With PCOS
Completed NCT05981742 - Effects of Combined Metformin and Cabergoline in Comparison With Metformin Only Therapy on Ovarian and Hormonal Activities in Iraqi Patients With PCOS Phase 2
Completed NCT05702957 - Letrozole vs Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovarian Syndrome Phase 2/Phase 3
Completed NCT05029492 - Effect of Visceral Manipulation on PCOS N/A
Completed NCT02924025 - Motivational Interviewing as an Intervention for PCOS N/A
Not yet recruiting NCT02255578 - Endobarrier Treatment in Women With PCOS Phase 3
Not yet recruiting NCT00883259 - Metformin and Gestational Diabetes in High-risk Patients: a RCTs Phase 4
Withdrawn NCT01638988 - Clomifene Citrate Versus Metformin in First-line Treatment of Infertility in Patients With Polycystic Ovary Syndrome and a Resistance to Insulin Phase 3
Completed NCT02098668 - Mathematical Model for the Human Menstrual Cycle, Endocrinological Diseases and Fertility Treatment-PAEON N/A
Completed NCT01462864 - Development of a Structured Education Programme for Women With Polycystic Ovary Syndrome N/A
Recruiting NCT01431352 - Letrozole Versus Chinese Herbal Medicine on Polycystic Ovary Syndrome (PCOS) N/A
Completed NCT00989781 - Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome N/A